T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen-presenting cells or tumour cells to down-regulate T cell and natural killer (NK) cell functions. TIGIT has emerged as a key inhibitor of anti-tumour responses that can hinder multiple steps of the cancer immunity cycle. Pre-clinical studies indicated that TIGIT blockade may protect against various solid and haematological cancers. Several monoclonal antibodies (mAbs) that block the inhibitory activity of human TIGIT have been developed. Clinical trials are ongoing, investigating TIGIT blockade as a monotherapy or in combination with anti-PD1/PD-L1 mAbs for the treatment of patients with advanced solid malignancies. In this review, we cover our current knowledge on TIGIT, from its discovery in 2009 to its current status as a clinical target.

中文翻译：

---

TIGIT作为新兴的免疫检查站。

T细胞免疫球蛋白和ITIM结构域（TIGIT）是淋巴细胞上表达的一种抑制性受体，最近在聚光灯下被推动为癌症免疫治疗的主要新兴靶标。TIGIT与抗原呈递细胞或肿瘤细胞上表达的CD155相互作用，以下调T细胞和自然杀伤（NK）细胞的功能。TIGIT已经成为抗肿瘤反应的关键抑制剂，它可以阻碍癌症免疫周期的多个步骤。临床前研究表明，TIGIT阻断剂可以预防各种实体和血液癌症。已经开发出几种阻断人TIGIT抑制活性的单克隆抗体（mAb）。正在进行临床试验，研究将TIGIT阻断疗法作为单一疗法或与抗PD1 / PD-L1 mAb结合用于治疗晚期实体恶性肿瘤的患者。在这篇综述中，我们涵盖了我们对TIGIT的当前了解，从2009年的发现到其目前的临床目标。